APR Energy Announces EPP Gas Generation Project In Rio de Janeiro

APR Energy Ltd. ("APR"), a wholly-owned subsidiary of Atlas Corp. ("Atlas" or the "Company") (NYSE:ATCO), announced today that it will provide Evolution Power Partners ("EPP") with

APR Energy Ltd. (“APR”), a wholly-owned subsidiary of Atlas Corp. (“Atlas” or the “Company”) (NYSE:ATCO), announced today that it will provide Evolution Power Partners (“EPP”) with 228 MW of gas generation capacity for a minimum of one year. APR’s solution for EPP includes a full turn-key natural gas-fired power plant powered by eight GE TM2500 gas turbines in Itaguaí, Rio De Janeiro with a commercial operation date of May 1, 2022.

APR’s work will support EPP’s award in the October 2021 simplified competitive procedure emergency auction held by ANEEL, Brazil’s National Electricity Regulatory Agency. ANEEL’s reserve energy auctions were driven by a need by Brazil to mitigate the worst drought in 91 years impacting the availability of hydro power in the country.

“Fulfilling Brazil’s energy needs takes innovation, reliability and proven results. Our new partnership with APR Energy exemplifies this approach. APR brings a track record of executing energy projects in a range of configurations and jurisdictions across the world,” said Mauricio Carvalho of EPP. 

APR has deployed over five GW of short- and long-term power projects in 35 markets around the world over the last 15 years. This contract represents APR’s first project in Brazil.

“We are thrilled to be entering the dynamic and growing Brazilian market by partnering with a trusted industry leader such as EPP,” said Ben Church, CEO, APR Energy. “APR is committed to Brazil in the long-term. We look forward to supporting the citizens of Brazil with sustainable and reliable power through the energy transition and beyond.”

Total
0
Shares
Related Posts
Read More

Verastem Oncology On Sunday Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data Of VS-6766 With Defactinib In Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates And Progression-Free Survival Presented at ESMO 2021

Median progression-free survival (mPFS) across all patients treated with VS-6766 in combination with defactinib in the study is 23.0 months. 11 of 24 (46%) patients treated with the combination achieved a confirmed

VSTM